Diagnostic Products profiles IMMULITE 1000:
This article was originally published in Clinica
US company Diagnostic Products is gearing up to launch its IMMULITE 1000 automated immunoassay later this year. The product has a number of enhancements, such as a remote diagnostics capability, onboard dilutions and positive secondary sample identification. The IMMULITE 1000 has an "unrivalled breadth of almost 100 assays" and includes routine tests for cardiac status, thyroid function, reproductive endocrinology and tumour markers, says Diagnostic Products. The system can also run esoteric tests for infectious disease, diabetes and bone metabolism, says the Los Angeles, California firm.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.